{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T11:19:01Z","timestamp":1767871141249,"version":"3.49.0"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Appl Genetics"],"DOI":"10.1007\/s13353-025-01041-8","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:34:10Z","timestamp":1767850450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epstein\u2013barr virus and multiple sclerosis: from pathogenesis and diagnosis to EBV-specific T cell therapy and gene-targeted therapeutics"],"prefix":"10.1007","author":[{"given":"Mukesh","family":"Pushkarna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Zwamel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Malathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukhlisa","family":"Mustafayeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali M. Ali","family":"Al-Nuaimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beneen","family":"Husseen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7272-3804","authenticated-orcid":false,"given":"Mohammad","family":"Dahghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"7","key":"1041_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/jnnp-2020-322941","volume":"91","author":"S Abrahamyan","year":"2020","unstructured":"Abrahamyan S et al (2020) Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. J Neurol Neurosurg Psychiatry 91(7):681\u2013686","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1041_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41598-019-55850-z","volume":"10","author":"A Afrasiabi","year":"2020","unstructured":"Afrasiabi A et al (2020) The interaction of multiple sclerosis risk loci with Epstein-Barr virus phenotypes implicates the virus in pathogenesis. Sci Rep 10(1):193","journal-title":"Sci Rep"},{"issue":"6","key":"1041_CR3","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.3390\/ijms22062927","volume":"22","author":"A Afrasiabi","year":"2021","unstructured":"Afrasiabi A et al (2021) The interaction of human and epstein\u2013barr virus Mirnas with multiple sclerosis risk loci. Int J Mol Sci 22(6):2927","journal-title":"Int J Mol Sci"},{"issue":"42","key":"1041_CR4","doi-asserted-by":"publisher","first-page":"pE6467","DOI":"10.1073\/pnas.1605884113","volume":"113","author":"M Albanese","year":"2016","unstructured":"Albanese M et al (2016) Epstein\u2013Barr virus MicroRNAs reduce immune surveillance by virus-specific CD8\u2009+\u2009T cells. Proc Natl Acad Sci 113(42):pE6467\u2013E6475","journal-title":"Proc Natl Acad Sci"},{"issue":"02","key":"1041_CR5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4103\/ijmpo.ijmpo_132_17","volume":"39","author":"S Amoueian","year":"2018","unstructured":"Amoueian S et al (2018) Epstein\u2013Barr virus infection in adult patients with gastric cancer in Northeast of Iran. Indian J Med Pediatr Oncol 39(02):206\u2013209","journal-title":"Indian J Med Pediatr Oncol"},{"issue":"2","key":"1041_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.cytogfr.2014.10.010","volume":"26","author":"V Annibali","year":"2015","unstructured":"Annibali V et al (2015) IFN-\u03b2 and multiple sclerosis: from etiology to therapy and back. Cytokine Growth Factor Rev 26(2):221\u2013228","journal-title":"Cytokine Growth Factor Rev"},{"issue":"24","key":"1041_CR7","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1001\/jama.286.24.3083","volume":"286","author":"A Ascherio","year":"2001","unstructured":"Ascherio A et al (2001) Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286(24):3083\u20133088","journal-title":"JAMA"},{"issue":"11","key":"1041_CR8","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/nrneurol.2012.198","volume":"8","author":"A Ascherio","year":"2012","unstructured":"Ascherio A, Munger KL, L\u00fcnemann JD (2012) The initiation and prevention of multiple sclerosis. Nat Rev Neurol 8(11):602\u2013612","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"1041_CR9","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3390\/diagnostics13081448","volume":"13","author":"MS Attia","year":"2023","unstructured":"Attia MS et al (2023) Altered Lnc-EGFR, SNHG1, and LincRNA-Cox2 profiles in patients with relapsing-remitting multiple sclerosis: impact on disease activity and progression. Diagnostics 13(8):1448","journal-title":"Diagnostics"},{"issue":"7","key":"1041_CR10","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/jnnp.2004.045500","volume":"76","author":"H Axer","year":"2005","unstructured":"Axer H et al (2005) Initial DWI and ADC imaging May predict outcome in acute disseminated encephalomyelitis: report of two cases of brain stem encephalitis. J Neurol Neurosurg Psychiatry 76(7):996\u2013998","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"22","key":"1041_CR11","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.2217\/epi-2021-0296","volume":"13","author":"H Azari","year":"2021","unstructured":"Azari H et al (2021) Construction of a lncRNA\u2013miRNA\u2013mRNA network to determine the key regulators of the Th1\/Th2 imbalance in multiple sclerosis. Epigenomics 13(22):1797\u20131815","journal-title":"Epigenomics"},{"issue":"1","key":"1041_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jis646","volume":"207","author":"HH Balfour Jr","year":"2013","unstructured":"Balfour HH Jr et al (2013) Behavioral, virologic, and Immunologic factors associated with acquisition and severity of primary Epstein\u2013Barr virus infection in university students. J Infect Dis 207(1):80\u201388","journal-title":"J Infect Dis"},{"issue":"2","key":"1041_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136(2):215\u2013233","journal-title":"Cell"},{"issue":"416","key":"1041_CR14","first-page":"pe70","volume":"2007","author":"EN Benveniste","year":"2007","unstructured":"Benveniste EN, Qin H (2007) Type I interferons as anti-inflammatory mediators. Science\u2019s STKE 2007(416):pe70\u2013pe70","journal-title":"Science\u2019s STKE"},{"issue":"6578","key":"1041_CR15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik K et al (2022) Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 375(6578):296\u2013301","journal-title":"Science"},{"issue":"3","key":"1041_CR16","first-page":"160","volume":"19","author":"K Bjornevik","year":"2023","unstructured":"Bjornevik K et al (2023) Epstein\u2013Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. Nat Reviews Neurol 19(3):160\u2013171","journal-title":"Nat Reviews Neurol"},{"key":"1041_CR17","unstructured":"Bronge M (2023) Identification of autoantigens in multiple sclerosis. Karolinska Institutet (Sweden"},{"issue":"5","key":"1041_CR18","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","volume":"50","author":"W Bu","year":"2019","unstructured":"Bu W et al (2019) Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein-Barr virus in B cells and epithelial cells. Immunity 50(5):1305\u20131316e6","journal-title":"Immunity"},{"issue":"10","key":"1041_CR19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41583-018-0057-5","volume":"19","author":"O Butovsky","year":"2018","unstructured":"Butovsky O, Weiner HL (2018) Microglial signatures and their role in health and disease. Nat Rev Neurosci 19(10):622\u2013635","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"1041_CR20","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1172\/JCI200523661","volume":"115","author":"S Cepok","year":"2005","unstructured":"Cepok S et al (2005) Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Investig 115(5):1352\u20131360","journal-title":"J Clin Investig"},{"issue":"9","key":"1041_CR21","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ni.3771","volume":"18","author":"YG Chen","year":"2017","unstructured":"Chen YG, Satpathy AT, Chang HY (2017) Gene regulation in the immune system by long noncoding RNAs. Nat Immunol 18(9):962\u2013972","journal-title":"Nat Immunol"},{"issue":"1","key":"1041_CR22","doi-asserted-by":"publisher","first-page":"e1007535","DOI":"10.1371\/journal.ppat.1007535","volume":"15","author":"Y Chen","year":"2019","unstructured":"Chen Y et al (2019) Epstein-Barr virus MicroRNAs regulate B cell receptor signal transduction and lytic reactivation. PLoS Pathog 15(1):e1007535","journal-title":"PLoS Pathog"},{"issue":"5","key":"1041_CR23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/1352458511426816","volume":"18","author":"M Comabella","year":"2012","unstructured":"Comabella M et al (2012) EBV-specific immune responses in patients with multiple sclerosis responding to IFN\u03b2 therapy. Multiple Scler J 18(5):605\u2013609","journal-title":"Multiple Scler J"},{"key":"1041_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/B978-0-444-52001-2.00014-5","volume":"122","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, Vukusic S (2014) The clinical course of multiple sclerosis. Handb Clin Neurol 122:343\u2013369","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"1041_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/0090-1229(83)90009-0","volume":"29","author":"JC Craig","year":"1983","unstructured":"Craig JC et al (1983) Immunological control of Epstein-Barr virus-transformed lymphocytes in multiple sclerosis. Clin Immunol Immunopathol 29(1):86\u201393","journal-title":"Clin Immunol Immunopathol"},{"issue":"3","key":"1041_CR26","first-page":"548","volume":"61","author":"J Craig","year":"1985","unstructured":"Craig J et al (1985) Subsets of T lymphocytes in relation to T lymphocyte function in multiple sclerosis. Clin Exp Immunol 61(3):548","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"1041_CR27","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/WCO.0000000000001063","volume":"35","author":"BA Cree","year":"2022","unstructured":"Cree BA, Hartung H-P, Barnett M (2022) New drugs for multiple sclerosis: new treatment algorithms. Curr Opin Neurol 35(3):262\u2013270","journal-title":"Curr Opin Neurol"},{"key":"1041_CR28","doi-asserted-by":"publisher","first-page":"734471","DOI":"10.3389\/fimmu.2021.734471","volume":"12","author":"X Cui","year":"2021","unstructured":"Cui X, Snapper CM (2021) Epstein barr virus: development of vaccines and immune cell therapy for EBV-associated diseases. Front Immunol 12:734471","journal-title":"Front Immunol"},{"issue":"3","key":"1041_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3390\/vaccines9030285","volume":"9","author":"X Cui","year":"2021","unstructured":"Cui X et al (2021) Immunization with Epstein\u2013Barr virus core fusion machinery envelope proteins elicit high titers of neutralizing activities and protect humanized mice from lethal dose EBV challenge. Vaccines 9(3):285","journal-title":"Vaccines"},{"issue":"1","key":"1041_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1586\/14787210.1.1.21","volume":"1","author":"E De Clercq","year":"2003","unstructured":"De Clercq E (2003) Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections. Expert Rev Anti-infective Therapy 1(1):21\u201343","journal-title":"Expert Rev Anti-infective Therapy"},{"issue":"6","key":"1041_CR31","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1001\/archneur.63.6.noc50328","volume":"63","author":"GN DeLorenze","year":"2006","unstructured":"DeLorenze GN et al (2006) Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 63(6):839\u2013844","journal-title":"Arch Neurol"},{"issue":"9","key":"1041_CR32","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1101\/gr.132159.111","volume":"22","author":"T Derrien","year":"2012","unstructured":"Derrien T et al (2012) The GENCODE v7 catalog of human long noncoding rnas: analysis of their gene structure, evolution, and expression. Genome Res 22(9):1775\u20131789","journal-title":"Genome Res"},{"issue":"22","key":"1041_CR33","doi-asserted-by":"publisher","first-page":"12368","DOI":"10.1073\/pnas.2002392117","volume":"117","author":"N.C Drosu","year":"2020","unstructured":"Drosu N.C., Edelman E.R., Housman D.E. (2020) Tenofovir prodrugs potently inhibit Epstein\u2013Barr virus lytic DNA replication by targeting the viral DNA polymerase. Proc Natl Acad Sci 117(22):12368\u201312374","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"1041_CR34","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1128\/JVI.01409-07","volume":"82","author":"SL Elliott","year":"2008","unstructured":"Elliott SL et al (2008) Phase I trial of a CD8\u2009+\u2009T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol 82(3):1448\u20131457","journal-title":"J Virol"},{"issue":"6043","key":"1041_CR35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/318287a0","volume":"318","author":"M Epstein","year":"1985","unstructured":"Epstein M et al (1985) Protection of Cottontop tamarins against Epstein\u2013Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 318(6043):287\u2013289","journal-title":"Nature"},{"issue":"7","key":"1041_CR36","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1089\/vim.2015.0035","volume":"28","author":"GL Erre","year":"2015","unstructured":"Erre GL et al (2015) Increased Epstein-Barr virus DNA load and antibodies against EBNA1 and EA in Sardinian patients with rheumatoid arthritis. Viral Immunol 28(7):385\u2013390","journal-title":"Viral Immunol"},{"issue":"2","key":"1041_CR37","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3390\/vaccines8020169","volume":"8","author":"GM Escalante","year":"2020","unstructured":"Escalante GM et al (2020) A pentavalent Epstein-Barr virus-like particle vaccine elicits high titers of neutralizing antibodies against Epstein-Barr virus infection in immunized rabbits. Vaccines 8(2):169","journal-title":"Vaccines"},{"issue":"1","key":"1041_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1212\/WNL.0b013e3181aa29fe","volume":"73","author":"R Farrell","year":"2009","unstructured":"Farrell R et al (2009) Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 73(1):32\u201338","journal-title":"Neurology"},{"issue":"1","key":"1041_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrg3606","volume":"15","author":"A Fatica","year":"2014","unstructured":"Fatica A, Bozzoni I (2014) Long non-coding rnas: new players in cell differentiation and development. Nat Rev Genet 15(1):7\u201321","journal-title":"Nat Rev Genet"},{"issue":"12","key":"1041_CR40","doi-asserted-by":"publisher","first-page":"6889","DOI":"10.1128\/JVI.07056-11","volume":"86","author":"E Forte","year":"2012","unstructured":"Forte E et al (2012) The Epstein-Barr virus (EBV)-induced tumor suppressor MicroRNA MiR-34a is growth promoting in EBV-infected B cells. J Virol 86(12):6889\u20136898","journal-title":"J Virol"},{"issue":"1\u20132","key":"1041_CR41","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jneuroim.2010.10.027","volume":"230","author":"D Franciotta","year":"2011","unstructured":"Franciotta D et al (2011) Cerebrospinal BAFF and Epstein\u2013Barr virus-specific oligoclonal bands in multiple sclerosis and other inflammatory demyelinating neurological diseases. J Neuroimmunol 230(1\u20132):160\u2013163","journal-title":"J Neuroimmunol"},{"issue":"3","key":"1041_CR42","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1191\/1352458505ms1185oa","volume":"11","author":"J Friedman","year":"2005","unstructured":"Friedman J et al (2005) A randomized clinical trial of valacyclovir in multiple sclerosis. Multiple Scler J 11(3):286\u2013295","journal-title":"Multiple Scler J"},{"issue":"4","key":"1041_CR43","doi-asserted-by":"publisher","first-page":"e0175279","DOI":"10.1371\/journal.pone.0175279","volume":"12","author":"RM Gie\u00df","year":"2017","unstructured":"Gie\u00df RM et al (2017) Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis. PLoS ONE 12(4):e0175279","journal-title":"PLoS ONE"},{"issue":"6","key":"1041_CR44","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1212\/WNL.55.6.842","volume":"55","author":"E Granieri","year":"2000","unstructured":"Granieri E et al (2000) The increasing incidence and prevalence of MS in a Sardinian Province. Neurology 55(6):842\u2013848","journal-title":"Neurology"},{"issue":"1","key":"1041_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25119","volume":"83","author":"AL Greenfield","year":"2018","unstructured":"Greenfield AL, Hauser SL (2018) B-cell therapy for multiple sclerosis: entering an era. Ann Neurol 83(1):13\u201326","journal-title":"Ann Neurol"},{"issue":"3","key":"1041_CR46","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4103\/1673-5374.245462","volume":"14","author":"Y Guan","year":"2019","unstructured":"Guan Y et al (2019) The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging. Neural Regeneration Res 14(3):373","journal-title":"Neural Regeneration Res"},{"issue":"15","key":"1041_CR47","doi-asserted-by":"publisher","first-page":"10040","DOI":"10.1128\/JVI.79.15.10040-10052.2005","volume":"79","author":"AM Hahn","year":"2005","unstructured":"Hahn AM et al (2005) Interferon regulatory factor 7 is negatively regulated by the Epstein-Barr virus immediate-early gene, BZLF-1. J Virol 79(15):10040\u201310052","journal-title":"J Virol"},{"issue":"2","key":"1041_CR48","doi-asserted-by":"publisher","first-page":"e0192109","DOI":"10.1371\/journal.pone.0192109","volume":"13","author":"A Hassani","year":"2018","unstructured":"Hassani A et al (2018) Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and May engage more than just B cells. PLoS ONE 13(2):e0192109","journal-title":"PLoS ONE"},{"key":"1041_CR49","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3389\/fimmu.2019.00695","volume":"10","author":"A Hassani","year":"2019","unstructured":"Hassani A, Khan G (2019) Epstein-barr virus and mirnas: partners in crime in the pathogenesis of multiple sclerosis? Front Immunol 10:695","journal-title":"Front Immunol"},{"issue":"2","key":"1041_CR50","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000095699","volume":"56","author":"T Henze","year":"2006","unstructured":"Henze T, Rieckmann P, Toyka K (2006) Symptomatic treatment of multiple sclerosis: Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society1. Eur Neurol 56(2):78\u2013105","journal-title":"Eur Neurol"},{"issue":"5","key":"1041_CR51","first-page":"925","volume":"115","author":"HE Heslop","year":"2010","unstructured":"Heslop HE et al (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood J Am Soc Hematol 115(5):925\u2013935","journal-title":"Blood J Am Soc Hematol"},{"issue":"3","key":"1041_CR52","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(15)00313-0","volume":"15","author":"R Hohlfeld","year":"2016","unstructured":"Hohlfeld R et al (2016) The search for the target antigens of multiple sclerosis, part 2: CD8\u2009+\u2009T cells, B cells, and antibodies in the focus of reverse-translational research. Lancet Neurol 15(3):317\u2013331","journal-title":"Lancet Neurol"},{"key":"1041_CR53","doi-asserted-by":"crossref","unstructured":"Hu W, Lucchinetti CF (2009) The pathological spectrum of CNS Inflammatory demyelinating diseases. In Seminars In immunopathology. Springer","DOI":"10.1007\/s00281-009-0178-z"},{"issue":"6","key":"1041_CR54","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","volume":"73","author":"EP Hui","year":"2013","unstructured":"Hui EP et al (2013) Phase I trial of Recombinant modified vaccinia Ankara encoding Epstein\u2013Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res 73(6):1676\u20131688","journal-title":"Cancer Res"},{"issue":"3","key":"1041_CR55","first-page":"140","volume":"41","author":"KL Hung","year":"2000","unstructured":"Hung KL, Liao HT, Tsai ML (2000) Epstein-Barr virus encephalitis in children. Acta Paediatr Sin 41(3):140\u2013146","journal-title":"Acta Paediatr Sin"},{"key":"1041_CR56","doi-asserted-by":"publisher","first-page":"652811","DOI":"10.3389\/fneur.2021.652811","volume":"12","author":"ZA Ioannides","year":"2021","unstructured":"Ioannides ZA et al (2021) Sustained clinical improvement in a subset of patients with progressive multiple sclerosis treated with Epstein\u2013Barr virus-specific T cell therapy. Front Neurol 12:652811","journal-title":"Front Neurol"},{"issue":"9","key":"1041_CR57","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1097\/nen.0b013e3181492a7","volume":"66","author":"CS Jack","year":"2007","unstructured":"Jack CS et al (2007) Th1 polarization of CD4\u2009+\u2009T cells by Toll-like receptor 3-activated human microglia. J Neuropathology Experimental Neurol 66(9):848\u2013859","journal-title":"J Neuropathology Experimental Neurol"},{"key":"1041_CR58","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a032003","author":"D Jakimovski","year":"2018","unstructured":"Jakimovski D et al (2018) Interferon \u03b2 for multiple sclerosis. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a032003","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"1041_CR59","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/eji.200939761","volume":"40","author":"E Jaqui\u00e9ry","year":"2010","unstructured":"Jaqui\u00e9ry E et al (2010) Intrathecal immune responses to EBV in early MS. Eur J Immunol 40(3):878\u2013887","journal-title":"Eur J Immunol"},{"issue":"1","key":"1041_CR60","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","volume":"175","author":"I Jelcic","year":"2018","unstructured":"Jelcic I et al (2018) Memory B cells activate brain-homing, autoreactive CD4\u2009+\u2009T cells in multiple sclerosis. Cell 175(1):85\u2013100e23","journal-title":"Cell"},{"issue":"9","key":"1041_CR61","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.4049\/jimmunol.1103100","volume":"188","author":"S Jilek","year":"2012","unstructured":"Jilek S et al (2012) HLA-B7\u2013restricted EBV-specific CD8\u2009+\u2009T cells are dysregulated in multiple sclerosis. J Immunol 188(9):4671\u20134680","journal-title":"J Immunol"},{"issue":"3","key":"1041_CR62","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1542\/pir.26.3.79","volume":"26","author":"AK Junker","year":"2005","unstructured":"Junker AK (2005) Epstein-Barr virus. Pediatr Rev 26(3):79\u201385","journal-title":"Pediatr Rev"},{"key":"1041_CR63","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s11864-013-0231-y","volume":"14","author":"JA Kanakry","year":"2013","unstructured":"Kanakry JA, Ambinder RF (2013) EBV-related lymphomas: new approaches to treatment. Curr Treat Options Oncol 14:224\u2013236","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"1041_CR64","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","volume":"162","author":"M Kanekiyo","year":"2015","unstructured":"Kanekiyo M et al (2015) Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site. Cell 162(5):1090\u20131100","journal-title":"Cell"},{"issue":"5830","key":"1041_CR65","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1126\/science.1138341","volume":"316","author":"P Kapranov","year":"2007","unstructured":"Kapranov P et al (2007) RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 316(5830):1484\u20131488","journal-title":"Science"},{"key":"1041_CR66","first-page":"324","volume":"2","author":"O Kastrup","year":"2005","unstructured":"Kastrup O, Wanke I, Maschke M (2005) Neuroimaging Infections NeuroRx 2:324\u2013332","journal-title":"Neuroimaging Infections NeuroRx"},{"issue":"1","key":"1041_CR67","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1146\/annurev.micro.54.1.19","volume":"54","author":"R Khanna","year":"2000","unstructured":"Khanna R, Burrows SR (2000) Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol 54(1):19\u201348","journal-title":"Annu Rev Microbiol"},{"key":"1041_CR68","unstructured":"Khirsariya P (2019) New organic compounds with targeted biological activity. Masarykova univerzita, P\u0159\u00edrodov\u011bdeck\u00e1 fakulta"},{"issue":"24","key":"1041_CR69","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.2174\/0929867325666180309105519","volume":"27","author":"K K\u0142ysik","year":"2020","unstructured":"K\u0142ysik K et al (2020) Acyclovir in the treatment of herpes viruses\u2013a review. Curr Med Chem 27(24):4118\u20134137","journal-title":"Curr Med Chem"},{"issue":"4","key":"1041_CR70","first-page":"1020","volume":"2","author":"B Krone","year":"2015","unstructured":"Krone B, Grange J (2015) Darwinian factors in the clinical expression of multiple sclerosis. Austin J Mult Scler Neuroimmunol 2(4):1020","journal-title":"Austin J Mult Scler Neuroimmunol"},{"issue":"3","key":"1041_CR71","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1534\/genetics.112.146704","volume":"193","author":"JT Kung","year":"2013","unstructured":"Kung JT, Colognori D, Lee JT (2013) Long noncoding rnas: past, present, and future. Genetics 193(3):651\u2013669","journal-title":"Genetics"},{"issue":"7","key":"1041_CR72","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3390\/v15071510","volume":"15","author":"N Lambert","year":"2023","unstructured":"Lambert N et al (2023) Virus-Specific T-Cell therapy for viral infections of the central nervous system: A review. Viruses 15(7):1510","journal-title":"Viruses"},{"key":"1041_CR73","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028936","author":"H Lassmann","year":"2018","unstructured":"Lassmann H (2018) Multiple sclerosis pathology. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a028936","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1041_CR74","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","volume":"9","author":"H Lassmann","year":"2019","unstructured":"Lassmann H (2019) Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol 9:3116","journal-title":"Front Immunol"},{"issue":"1","key":"1041_CR75","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/ane.12417","volume":"133","author":"L Latham","year":"2016","unstructured":"Latham L et al (2016) Antivirus immune activity in multiple sclerosis correlates with MRI activity. Acta Neurol Scand 133(1):17\u201324","journal-title":"Acta Neurol Scand"},{"key":"1041_CR76","doi-asserted-by":"publisher","first-page":"106507","DOI":"10.1016\/j.clineuro.2021.106507","volume":"202","author":"G-H Lee","year":"2021","unstructured":"Lee G-H et al (2021) Clinical significance of Epstein-Barr virus in the cerebrospinal fluid of immunocompetent patients. Clin Neurol Neurosurg 202:106507","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"1041_CR77","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/ana.21978","volume":"67","author":"LI Levin","year":"2010","unstructured":"Levin LI et al (2010) Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 67(6):824\u2013830","journal-title":"Ann Neurol"},{"issue":"2","key":"1041_CR78","doi-asserted-by":"publisher","first-page":"e976507","DOI":"10.4161\/23723556.2014.976507","volume":"4","author":"J Li","year":"2015","unstructured":"Li J et al (2015) Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Oncoimmunology 4(2):e976507","journal-title":"Oncoimmunology"},{"issue":"23","key":"1041_CR79","first-page":"6952","volume":"62","author":"C-L Lin","year":"2002","unstructured":"Lin C-L et al (2002) Immunization with Epstein-Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8\u2009+\u2009T-cell immunity and May lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 62(23):6952\u20136958","journal-title":"Cancer Res"},{"issue":"1\u20132","key":"1041_CR80","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jneuroim.2010.08.009","volume":"229","author":"JW Lindsey","year":"2010","unstructured":"Lindsey JW, Hatfield LM (2010) Epstein-Barr virus and multiple sclerosis: cellular immune response and cross-reactivity. J Neuroimmunol 229(1\u20132):238\u2013242","journal-title":"J Neuroimmunol"},{"issue":"10","key":"1041_CR81","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/j.1468-1331.2010.03005.x","volume":"17","author":"JW Lindsey","year":"2010","unstructured":"Lindsey JW, Hatfield LM, Vu T (2010) Epstein\u2013Barr virus neutralizing and early antigen antibodies in multiple sclerosis. Eur J Neurol 17(10):1263\u20131269","journal-title":"Eur J Neurol"},{"issue":"1","key":"1041_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-016-0378-2","volume":"21","author":"Y Liu","year":"2021","unstructured":"Liu Y et al (2021) Long non-coding RNAs in Epstein\u2013Barr virus-related cancer. Cancer Cell Int 21(1):1\u201316","journal-title":"Cancer Cell Int"},{"key":"1041_CR83","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMe1715141","volume":"378","author":"DL Longo","year":"2018","unstructured":"Longo DL (2018) Daniel S. Reich, MD, Ph. D., Claudia F. Lucchinetti, MD, and Peter A. Calabresi, MD. N Engl J Med 378:169\u201380","journal-title":"N Engl J Med"},{"issue":"10","key":"1041_CR84","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1136\/jnnp-2011-300174","volume":"82","author":"R Lucas","year":"2011","unstructured":"Lucas R et al (2011) Epstein\u2013Barr virus and multiple sclerosis. J Neurol Neurosurg Psychiatry 82(10):1142\u20131148","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"1041_CR85","first-page":"707","volume":"47","author":"C Lucchinetti","year":"2000","unstructured":"Lucchinetti C et al (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Annals of Neurology. Official J Am Neurol Association Child Neurol Soc 47(6):707\u2013717","journal-title":"Official J Am Neurol Association Child Neurol Soc"},{"issue":"6","key":"1041_CR86","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awl067","volume":"129","author":"JD L\u00fcnemann","year":"2006","unstructured":"L\u00fcnemann JD et al (2006) Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 129(6):1493\u20131506","journal-title":"Brain"},{"issue":"8","key":"1041_CR87","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1084\/jem.20072397","volume":"205","author":"JD L\u00fcnemann","year":"2008","unstructured":"L\u00fcnemann JD et al (2008) EBNA1-specific T cells from patients with multiple sclerosis cross React with Myelin antigens and co-produce IFN-\u03b3 and IL-2. J Exp Med 205(8):1763\u20131773","journal-title":"J Exp Med"},{"issue":"2","key":"1041_CR88","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/ana.21886","volume":"67","author":"JD L\u00fcnemann","year":"2010","unstructured":"L\u00fcnemann JD et al (2010) Elevated Epstein\u2013Barr virus-encoded nuclear antigen\u20101 immune responses predict conversion to multiple sclerosis. Annals Neurology: Official J Am Neurol Association Child Neurol Soc 67(2):159\u2013169","journal-title":"Annals Neurology: Official J Am Neurol Association Child Neurol Soc"},{"issue":"1","key":"1041_CR89","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.pathophys.2010.04.003","volume":"18","author":"A-H Maghzi","year":"2011","unstructured":"Maghzi A-H et al (2011) Viral pathophysiology of multiple sclerosis: a role for Epstein-Barr virus infection? Pathophysiology 18(1):13\u201320","journal-title":"Pathophysiology"},{"issue":"1","key":"1041_CR90","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/NEN.0b013e31827bfc62","volume":"72","author":"R Magliozzi","year":"2013","unstructured":"Magliozzi R et al (2013) B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J Neuropathology Experimental Neurol 72(1):29\u201341","journal-title":"J Neuropathology Experimental Neurol"},{"issue":"19","key":"1041_CR91","doi-asserted-by":"publisher","first-page":"11166","DOI":"10.1128\/JVI.01785-14","volume":"88","author":"S Mansouri","year":"2014","unstructured":"Mansouri S et al (2014) Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 MicroRNA and Dicer. J Virol 88(19):11166\u201311177","journal-title":"J Virol"},{"key":"1041_CR92","doi-asserted-by":"publisher","first-page":"887794","DOI":"10.3389\/fneur.2022.887794","volume":"13","author":"PA Maple","year":"2022","unstructured":"Maple PA et al (2022) The potential for EBV vaccines to prevent multiple sclerosis. Front Neurol 13:887794","journal-title":"Front Neurol"},{"issue":"5512","key":"1041_CR93","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1126\/science.1058867","volume":"291","author":"D Masopust","year":"2001","unstructured":"Masopust D et al (2001) Preferential localization of effector memory cells in nonlymphoid tissue. Science 291(5512):2413\u20132417","journal-title":"Science"},{"issue":"6","key":"1041_CR94","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1177\/1352458516664210","volume":"23","author":"A Mathias","year":"2017","unstructured":"Mathias A et al (2017) Increased ex vivo antigen presentation profile of B cells in multiple sclerosis. Multiple Scler J 23(6):802\u2013809","journal-title":"Multiple Scler J"},{"issue":"22","key":"1041_CR95","first-page":"2351","volume":"132","author":"LP McLaughlin","year":"2018","unstructured":"McLaughlin LP et al (2018) EBV\/LMP-specific T cells maintain remissions of T-and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. J Am Soc Hematol 132(22):2351\u20132361","journal-title":"J Am Soc Hematol"},{"key":"1041_CR96","doi-asserted-by":"crossref","unstructured":"Melchers F, Rolink A (2006) B cell tolerance\u2014how to make it and how to break it. Current Concepts in Autoimmunity and Chronic Inflammation, :1\u201323","DOI":"10.1007\/3-540-29714-6_1"},{"issue":"6","key":"1041_CR97","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1600-0404.1997.tb00309.x","volume":"96","author":"E Merelli","year":"1997","unstructured":"Merelli E et al (1997) Encephalomyeloradiculopathy associated with Epstein-Barr virus: primary infection or reactivation? Acta Neurol Scand 96(6):416\u2013420","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"1041_CR98","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41587-019-0404-8","volume":"38","author":"DG Millar","year":"2020","unstructured":"Millar DG et al (2020) Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat Biotechnol 38(4):420\u2013425","journal-title":"Nat Biotechnol"},{"issue":"2","key":"1041_CR99","doi-asserted-by":"publisher","first-page":"435","DOI":"10.4049\/jimmunol.1700178","volume":"199","author":"E Morandi","year":"2017","unstructured":"Morandi E et al (2017) EBV infection empowers human B cells for autoimmunity: role of autophagy and relevance to multiple sclerosis. J Immunol 199(2):435\u2013448","journal-title":"J Immunol"},{"issue":"1","key":"1041_CR100","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4161\/rna.27488","volume":"11","author":"WN Moss","year":"2014","unstructured":"Moss WN et al (2014) RNA families in Epstein\u2013Barr virus. RNA Biol 11(1):10\u201317","journal-title":"RNA Biol"},{"issue":"24","key":"1041_CR101","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","volume":"25","author":"M Moutschen","year":"2007","unstructured":"Moutschen M et al (2007) Phase I\/II studies to evaluate safety and immunogenicity of a Recombinant gp350 Epstein\u2013Barr virus vaccine in healthy adults. Vaccine 25(24):4697\u20134705","journal-title":"Vaccine"},{"issue":"8","key":"1041_CR102","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1007\/s00262-021-03125-w","volume":"71","author":"J Ning","year":"2022","unstructured":"Ning J et al (2022) Functional virus-specific memory T cells survey glioblastoma. Cancer Immunol Immunother 71(8):1863\u20131875","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"1041_CR103","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/1352458512449682","volume":"19","author":"J Pakpoor","year":"2013","unstructured":"Pakpoor J et al (2013) The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Multiple Scler J 19(2):162\u2013166","journal-title":"Multiple Scler J"},{"issue":"10","key":"1041_CR104","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1038\/cti.2014.25","volume":"3","author":"MP Pender","year":"2014","unstructured":"Pender MP, Burrows SR (2014) Epstein\u2013Barr virus and multiple sclerosis: potential opportunities for immunotherapy. Clin Translational Immunol 3(10):e27","journal-title":"Clin Translational Immunol"},{"issue":"12","key":"1041_CR105","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1093\/brain\/awp312","volume":"132","author":"MP Pender","year":"2009","unstructured":"Pender MP (2009) Does Epstein\u2013Barr virus infection in the brain drive the development of multiple sclerosis? Brain 132(12):3196\u20133198","journal-title":"Brain"},{"issue":"4","key":"1041_CR106","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/1073858410381531","volume":"17","author":"MP Pender","year":"2011","unstructured":"Pender MP (2011) The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist 17(4):351\u2013367","journal-title":"Neuroscientist"},{"issue":"14","key":"1041_CR107","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1177\/1352458514536252","volume":"20","author":"MP Pender","year":"2014","unstructured":"Pender MP et al (2014a) Deficiency of CD8\u2009+\u2009effector memory T cells is an early and persistent feature of multiple sclerosis. Multiple Scler J 20(14):1825\u20131832","journal-title":"Multiple Scler J"},{"issue":"11","key":"1041_CR108","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/1352458514521888","volume":"20","author":"MP Pender","year":"2014","unstructured":"Pender MP et al (2014b) Epstein\u2013Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. Multiple Scler J 20(11):1541\u20131544","journal-title":"Multiple Scler J"},{"issue":"1","key":"1041_CR109","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1038\/cti.2016.87","volume":"6","author":"MP Pender","year":"2017","unstructured":"Pender MP et al (2017) Defective T-cell control of Epstein\u2013Barr virus infection in multiple sclerosis. Clin Translational Immunol 6(1):e126","journal-title":"Clin Translational Immunol"},{"key":"1041_CR110","doi-asserted-by":"crossref","unstructured":"Pender MP et al (2018) Epstein-Barr virus\u2013specific T cell therapy for progressive multiple sclerosis. JCI Insight, 3(22)","DOI":"10.1172\/jci.insight.124714"},{"issue":"8","key":"1041_CR111","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/nbt.1914","volume":"29","author":"JR Prensner","year":"2011","unstructured":"Prensner JR et al (2011) Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated LincRNA implicated in disease progression. Nat Biotechnol 29(8):742\u2013749","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1041_CR112","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0022-510X(99)00298-1","volume":"173","author":"KH Rand","year":"2000","unstructured":"Rand KH et al (2000) Epstein\u2013Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis. J Neurol Sci 173(1):32\u201339","journal-title":"J Neurol Sci"},{"issue":"1","key":"1041_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/vir.0.83391-0","volume":"89","author":"RE Randall","year":"2008","unstructured":"Randall RE, Goodbourn S (2008) Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89(1):1\u201347","journal-title":"J Gen Virol"},{"key":"1041_CR114","doi-asserted-by":"publisher","first-page":"103563","DOI":"10.1016\/j.msard.2022.103563","volume":"59","author":"X Rang","year":"2022","unstructured":"Rang X et al (2022) Identification of multiple sclerosis-related genes regulated by EBV-encoded MicroRNAs in B cells. Multiple Scler Relat Disorders 59:103563","journal-title":"Multiple Scler Relat Disorders"},{"issue":"9","key":"1041_CR115","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/icb.2016.55","volume":"94","author":"F Rizzo","year":"2016","unstructured":"Rizzo F et al (2016) Interferon-\u03b2 therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS\u2010mediated apoptosis. Immunol Cell Biol 94(9):886\u2013894","journal-title":"Immunol Cell Biol"},{"issue":"6578","key":"1041_CR116","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1126\/science.abm7930","volume":"375","author":"WH Robinson","year":"2022","unstructured":"Robinson WH, Steinman L (2022) Epstein-barr virus and multiple sclerosis. Science 375(6578):264\u2013265","journal-title":"Science"},{"issue":"1","key":"1041_CR117","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41467-019-08534-1","volume":"10","author":"PC Rosato","year":"2019","unstructured":"Rosato PC et al (2019) Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nat Commun 10(1):567","journal-title":"Nat Commun"},{"key":"1041_CR118","unstructured":"Rosen AR (2024) Vaccination against gammaherpesvirus attenuates viral enhanced disease in a murine model of multiple sclerosis. University of British Columbia"},{"issue":"8","key":"1041_CR119","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/pathogens11080864","volume":"11","author":"M Rozman","year":"2022","unstructured":"Rozman M et al (2022) Progress in prophylactic and therapeutic EBV vaccine development based on molecular characteristics of EBV target antigens. Pathogens 11(8):864","journal-title":"Pathogens"},{"issue":"24","key":"1041_CR120","doi-asserted-by":"publisher","first-page":"13105","DOI":"10.1128\/JVI.05598-11","volume":"85","author":"R Ruiss","year":"2011","unstructured":"Ruiss R et al (2011) A virus-like particle-based Epstein-Barr virus vaccine. J Virol 85(24):13105\u201313113","journal-title":"J Virol"},{"issue":"1\u20132","key":"1041_CR121","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jneuroim.2014.04.005","volume":"272","author":"K Ruprecht","year":"2014","unstructured":"Ruprecht K et al (2014) Multiple sclerosis: the elevated antibody response to Epstein\u2013Barr virus primarily targets, but is not confined to, the glycine\u2013alanine repeat of Epstein\u2013Barr nuclear antigen-1. J Neuroimmunol 272(1\u20132):56\u201361","journal-title":"J Neuroimmunol"},{"key":"1041_CR122","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s13760-018-0976-y","volume":"118","author":"A Saberi","year":"2018","unstructured":"Saberi A, Akhondzadeh S, Kazemi S (2018) Infectious agents and different course of multiple sclerosis: a systematic review. Acta Neurol Belg 118:361\u2013377","journal-title":"Acta Neurol Belg"},{"issue":"13","key":"1041_CR123","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00238-19","volume":"93","author":"A Saha","year":"2019","unstructured":"Saha A, Robertson ES (2019) Mechanisms of B-cell oncogenesis induced by Epstein-Barr virus. J Virol 93(13):10.1128\/jvi.00238\u2009\u2212\u200919","journal-title":"J Virol"},{"key":"1041_CR124","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.3389\/fimmu.2019.01962","volume":"10","author":"JP Sefrin","year":"2019","unstructured":"Sefrin JP et al (2019) Sensitization of tumors for attack by virus-specific CD8\u2009+\u2009T-cells through antibody-mediated delivery of Immunogenic T-cell epitopes. Front Immunol 10:1962","journal-title":"Front Immunol"},{"issue":"7","key":"1041_CR125","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/NEN.0b013e3181e332ec","volume":"69","author":"B Serafini","year":"2010","unstructured":"Serafini B et al (2010) Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathology Experimental Neurol 69(7):677\u2013693","journal-title":"J Neuropathology Experimental Neurol"},{"issue":"7","key":"1041_CR126","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/NEN.0000000000000082","volume":"73","author":"B Serafini","year":"2014","unstructured":"Serafini B et al (2014) Epstein-Barr virus in the central nervous system and cervical lymph node of a patient with primary progressive multiple sclerosis. J Neuropathol Exp Neurol 73(7):729\u2013731","journal-title":"J Neuropathol Exp Neurol"},{"issue":"24","key":"1041_CR127","doi-asserted-by":"publisher","first-page":"e00980","DOI":"10.1128\/JVI.00980-19","volume":"93","author":"B Serafini","year":"2019","unstructured":"Serafini B et al (2019) Epstein-Barr virus-specific CD8 T cells selectively infiltrate the brain in multiple sclerosis and interact locally with virus-infected cells: clue for a virus-driven immunopathological mechanism. J Virol 93(24):e00980\u2013e00919","journal-title":"J Virol"},{"issue":"8","key":"1041_CR128","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1248\/cpb.c16-00114","volume":"64","author":"Y Si","year":"2016","unstructured":"Si Y et al (2016) The safety and immunological effects of rAd5-EBV-LMP2 vaccine in nasopharyngeal carcinoma patients: a phase I clinical trial and two-year follow-up. Chem Pharm Bull 64(8):1118\u20131123","journal-title":"Chem Pharm Bull"},{"issue":"7706","key":"1041_CR129","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni Y et al (2018) Bystander CD8\u2009+\u2009T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557(7706):575\u2013579","journal-title":"Nature"},{"issue":"1","key":"1041_CR130","doi-asserted-by":"publisher","first-page":"205521731990129","DOI":"10.1177\/2055217319901291","volume":"6","author":"CS Simonsen","year":"2020","unstructured":"Simonsen CS et al (2020) The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis. Multiple Scler Journal\u2013Experimental Translational Clin 6(1):2055217319901291","journal-title":"Multiple Scler Journal\u2013Experimental Translational Clin"},{"key":"1041_CR131","doi-asserted-by":"crossref","unstructured":"Smith C, Khanna R (2015) The development of prophylactic and therapeutic EBV vaccines. Epstein Barr Virus Volume 2: One Herpes Virus: Many Diseases, : 455\u2013473","DOI":"10.1007\/978-3-319-22834-1_16"},{"issue":"12","key":"1041_CR132","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1086\/523813","volume":"196","author":"EM Sokal","year":"2007","unstructured":"Sokal EM et al (2007) Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 196(12):1749\u20131753","journal-title":"J Infect Dis"},{"issue":"1","key":"1041_CR133","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","volume":"21","author":"SS Soldan","year":"2023","unstructured":"Soldan SS, Lieberman PM (2023) Epstein\u2013Barr virus and multiple sclerosis. Nat Rev Microbiol 21(1):51\u201364","journal-title":"Nat Rev Microbiol"},{"issue":"70","key":"1041_CR134","doi-asserted-by":"publisher","first-page":"eabo7799","DOI":"10.1126\/sciimmunol.abo7799","volume":"7","author":"LM Sollid","year":"2022","unstructured":"Sollid LM (2022) Epstein-Barr virus as a driver of multiple sclerosis. Sci Immunol 7(70):eabo7799","journal-title":"Sci Immunol"},{"issue":"2","key":"1041_CR135","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s11033-021-06152-z","volume":"48","author":"S Soltani","year":"2021","unstructured":"Soltani S et al (2021) A review on EBV encoded and EBV-induced host MicroRNAs expression profile in different lymphoma types. Mol Biol Rep 48(2):1801\u20131817","journal-title":"Mol Biol Rep"},{"issue":"5","key":"1041_CR136","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/0891693031000151607","volume":"36","author":"S Stefano","year":"2003","unstructured":"Stefano S et al (2003) Review does the \u201cHygiene Hypothesis\u201d provide an explanation for the high prevalence of multiple sclerosis in Sardinia? Autoimmunity 36(5):257\u2013260","journal-title":"Autoimmunity"},{"key":"1041_CR137","unstructured":"Strautins K (2015) Investigating the role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Murdoch University"},{"issue":"2","key":"1041_CR138","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1084\/jem.20161846","volume":"214","author":"SG Tangye","year":"2017","unstructured":"Tangye SG, Palendira U, Edwards ES (2017) Human immunity against EBV\u2014lessons from the clinic. J Exp Med 214(2):269\u2013283","journal-title":"J Exp Med"},{"issue":"19","key":"1041_CR139","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","volume":"20","author":"GS Taylor","year":"2014","unstructured":"Taylor GS et al (2014) A Recombinant modified vaccinia Ankara vaccine encoding Epstein\u2013Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res 20(19):5009\u20135022","journal-title":"Clin Cancer Res"},{"key":"1041_CR140","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","volume":"33","author":"GS Taylor","year":"2015","unstructured":"Taylor GS et al (2015) The immunology of Epstein-Barr virus\u2013induced disease. Annu Rev Immunol 33:787\u2013821","journal-title":"Annu Rev Immunol"},{"issue":"34","key":"1041_CR141","doi-asserted-by":"publisher","first-page":"16955","DOI":"10.1073\/pnas.1902623116","volume":"116","author":"K Tengvall","year":"2019","unstructured":"Tengvall K et al (2019) Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. Proc Natl Acad Sci 116(34):16955\u201316960","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"1041_CR142","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/nm.4008","volume":"22","author":"JJ Thome","year":"2016","unstructured":"Thome JJ et al (2016) Early-life compartmentalization of human T cell differentiation and regulatory function in mucosal and lymphoid tissues. Nat Med 22(1):72\u201377","journal-title":"Nat Med"},{"key":"1041_CR143","doi-asserted-by":"crossref","unstructured":"Thorley-Lawson DA (2015) EBV persistence\u2014introducing the virus. Epstein Barr Virus Volume 1: One Herpes Virus: Many Diseases, : 151\u2013209","DOI":"10.1007\/978-3-319-22822-8_8"},{"key":"1041_CR144","doi-asserted-by":"publisher","first-page":"102569","DOI":"10.1016\/j.msard.2020.102569","volume":"46","author":"\u00d8 Torkildsen","year":"2020","unstructured":"Torkildsen \u00d8 et al (2020) Tenofovir as a treatment option for multiple sclerosis. Multiple Scler Relat Disorders 46:102569","journal-title":"Multiple Scler Relat Disorders"},{"issue":"17","key":"1041_CR145","doi-asserted-by":"publisher","first-page":"13609","DOI":"10.3390\/ijms241713609","volume":"24","author":"NH Trier","year":"2023","unstructured":"Trier NH, Houen G (2023) Antibody cross-reactivity in auto-immune diseases. Int J Mol Sci 24(17):13609","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1041_CR146","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/1352458515588581","volume":"22","author":"GP van Nierop","year":"2016","unstructured":"van Nierop GP et al (2016) Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins. Multiple Scler J 22(3):279\u2013291","journal-title":"Multiple Scler J"},{"issue":"1","key":"1041_CR147","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4049\/jimmunol.162.1.129","volume":"162","author":"AC Van Sechel","year":"1999","unstructured":"Van Sechel AC et al (1999) EBV-induced expression and HLA-DR-restricted presentation by human B cells of \u03b1B-crystallin, a candidate autoantigen in multiple sclerosis. J Immunol 162(1):129\u2013135","journal-title":"J Immunol"},{"key":"1041_CR148","doi-asserted-by":"publisher","first-page":"665718","DOI":"10.3389\/fimmu.2021.665718","volume":"12","author":"C Veroni","year":"2021","unstructured":"Veroni C, Aloisi F (2021) The CD8 T cell-Epstein-Barr virus-B cell trialogue: a central issue in multiple sclerosis pathogenesis. Front Immunol 12:665718","journal-title":"Front Immunol"},{"key":"1041_CR149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-017-1049-5","volume":"15","author":"C Veroni","year":"2018","unstructured":"Veroni C et al (2018) Transcriptional profile and Epstein-Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis. J Neuroinflamm 15:1\u201319","journal-title":"J Neuroinflamm"},{"issue":"1","key":"1041_CR150","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/1352458513490545","volume":"20","author":"J Virtanen","year":"2014","unstructured":"Virtanen J et al (2014) Oligoclonal bands in multiple sclerosis reactive against two herpesviruses and association with magnetic resonance imaging findings. Multiple Scler J 20(1):27\u201334","journal-title":"Multiple Scler J"},{"key":"1041_CR151","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1201\/b13907-11","volume-title":"Epstein-Barr virus and CNS infections, in Neuroviral infections","author":"A Volpi","year":"2013","unstructured":"Volpi A, Pica F (2013) Epstein-Barr virus and CNS infections, in Neuroviral infections. CRC, Boca Raton, Fl, pp 245\u2013272"},{"issue":"2","key":"1041_CR152","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1212\/WNL.55.2.178","volume":"55","author":"K-P Wandinger","year":"2000","unstructured":"Wandinger K-P et al (2000) Association between clinical disease activity and Epstein\u2013Barr virus reactivation in MS. Neurology 55(2):178\u2013184","journal-title":"Neurology"},{"key":"1041_CR153","doi-asserted-by":"publisher","first-page":"175628642311938","DOI":"10.1177\/17562864231193816","volume":"16","author":"M Wang","year":"2023","unstructured":"Wang M et al (2023) Recent progress in epidemiology, clinical features, and therapy of multiple sclerosis in China. Ther Adv Neurol Disord 16:17562864231193816","journal-title":"Ther Adv Neurol Disord"},{"issue":"643","key":"1041_CR154","doi-asserted-by":"publisher","first-page":"eabf3685","DOI":"10.1126\/scitranslmed.abf3685","volume":"14","author":"C-J Wei","year":"2022","unstructured":"Wei C-J et al (2022) A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice. Sci Transl Med 14(643):eabf3685","journal-title":"Sci Transl Med"},{"issue":"5","key":"1041_CR155","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/0092-8674(95)90348-8","volume":"80","author":"KW Wucherpfennig","year":"1995","unstructured":"Wucherpfennig KW, Strominger JL (1995) Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for Myelin basic protein. Cell 80(5):695\u2013705","journal-title":"Cell"},{"issue":"8","key":"1041_CR156","doi-asserted-by":"publisher","first-page":"e105434","DOI":"10.1371\/journal.pone.0105434","volume":"9","author":"SC Wuest","year":"2014","unstructured":"Wuest SC et al (2014) A complex role of herpes viruses in the disease process of multiple sclerosis. PLoS ONE 9(8):e105434","journal-title":"PLoS ONE"},{"key":"1041_CR157","doi-asserted-by":"crossref","unstructured":"Zhang Q, Xu M (2023a) EBV-induced T-cell responses in EBV-specific and nonspecific cancers. Front Immunol, 14","DOI":"10.3389\/fimmu.2023.1250946"},{"key":"1041_CR158","doi-asserted-by":"publisher","first-page":"1250946","DOI":"10.3389\/fimmu.2023.1250946","volume":"14","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Xu M (2023b) EBV-induced T-cell responses in EBV-specific and nonspecific cancers. Front Immunol 14:1250946","journal-title":"Front Immunol"},{"key":"1041_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.04.003","author":"Y Zhang","year":"2023","unstructured":"Zhang Y et al (2023) Epstein\u2012Barr virus\u2013associated cellular immunotherapy. Cytotherapy. https:\/\/doi.org\/10.1016\/j.jcyt.2023.04.003","journal-title":"Cytotherapy"},{"key":"1041_CR160","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000190","author":"R Zivadinov","year":"2016","unstructured":"Zivadinov R et al (2016) Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000190","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Journal of Applied Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13353-025-01041-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13353-025-01041-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13353-025-01041-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:02:30Z","timestamp":1767855750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13353-025-01041-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":160,"alternative-id":["1041"],"URL":"https:\/\/doi.org\/10.1007\/s13353-025-01041-8","relation":{},"ISSN":["1234-1983","2190-3883"],"issn-type":[{"value":"1234-1983","type":"print"},{"value":"2190-3883","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"5 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There is no conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}